Controlled Substances Quotas, 17329-17333 [2018-08111]

Agencies

• Drug Enforcement Administration
• Department of Justice

[Federal Register Volume 83, Number 76 (Thursday, April 19, 2018)]
[Proposed Rules]
[Pages 17329-17333]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-08111]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1303

[Docket No. DEA-480]
RIN 1117-AB48


Controlled Substances Quotas

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Notice of proposed rulemaking.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is publishing this 
proposed rule to strengthen controls over diversion of controlled 
substances and make other improvements in the quota management 
regulatory system for the production, manufacturing, and procurement of 
controlled substances.

DATES: Written comments must be postmarked, and electronic comments 
must be sent, on or before May 4, 2018. Comments received by mail will 
be considered timely if they are postmarked on or before the last day 
of the comment period. The electronic Federal Docket Management System 
will accept electronic comments until Midnight Eastern Time at the end 
of that day.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-480'' on all correspondence, including any attachment. 
The Drug Enforcement Administration encourages that all comments be 
submitted electronically through the Federal eRulemaking Portal which 
provides the ability to type short comments directly into the comment 
field on the web page or to attach a file for lengthier comments. 
Please go to https://www.regulations.gov and follow the online 
instructions at that site for submitting comments. Upon completion of 
your submission you will receive a Comment Tracking Number for your 
comment. Please be aware that submitted comments are not 
instantaneously available for public view on Regulations.gov. If you 
have received a Comment Tracking Number, your comment has been 
successfully submitted and there is no need to resubmit the same 
comment. Paper comments that duplicate the electronic submission are 
not necessary and are discouraged. Should you, however, wish to mail a 
paper comment in lieu of an electronic comment, it should be sent via 
regular or express mail to: Drug Enforcement Administration, Attention: 
DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control 
Division, Drug Enforcement Administration; Mailing Address: 8701 
Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-
8953.

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments

    Please note that all comments received are considered part of the 
public record. They will, unless reasonable cause is given, be made 
available by the Drug Enforcement Administration (DEA) for public 
inspection online at https://www.regulations.gov and in DEA's public 
docket. Such information includes personal identifying information 
(such as your name, address, etc.) voluntarily submitted by the 
commenter.
    If you want to submit personal identifying information (such as 
your name, address, etc.) as part of your comment, but do not want it 
to be posted online or made available in the public docket, you must 
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first 
paragraph of your comment. You must also place all the personal 
identifying information you do not want posted online or made available 
in the public docket in the first paragraph of your comment and 
identify what information you want redacted.
    If you want to submit confidential business information as part of 
your comment, but do not want it to be posted online or made available 
in the public docket, you must include the phrase ``CONFIDENTIAL 
BUSINESS INFORMATION'' in the first paragraph of your comment. You must 
also prominently identify confidential business information to be 
redacted within the comment. If a comment has so much confidential 
business information that it cannot be effectively redacted, all or 
part of that comment may not be posted online or made available in the 
public docket.
    Personal identifying information and confidential business 
information identified and located as set forth above will be redacted 
and the comment, in redacted form, will be posted online and placed in 
DEA's public docket file. Please note that the Freedom of Information 
Act applies to all comments received. If you wish to inspect the 
agency's public docket file in person by appointment, please see the 
FOR FURTHER INFORMATION paragraph.

Legal Authority

    Provisions of the Controlled Substances Act, 21 U.S.C. 801 et seq., 
authorize the Attorney General to issue rules and regulations relating 
to registration and control of the manufacture, distribution, and 
dispensing of controlled substances and listed chemicals. 21 U.S.C. 
821. Pursuant to this authority, the Attorney General, through the Drug 
Enforcement Administration (DEA), has issued and administers 
regulations setting aggregate production quotas for each basic class of 
controlled substances in schedules I and II, manufacturing quotas for 
individual manufacturers, and procurement quotas for manufacturers to 
produce other controlled substances or to convert the substances into 
dosage form. See 21 CFR part 1303.
    The current regulations, issued initially in 1971, need to be 
updated to reflect changes in the manufacture of controlled substances, 
changing patterns of substance abuse and markets in illicit drugs, and 
the challenges presented by the current national crisis of controlled 
substance abuse. This proposed rule modifies the regulations to 
strengthen controls over diversion--that is, the redirection of 
controlled substances which may have lawful uses into illicit 
channels--and makes other improvements in the controlled substance 
regulatory quota system.
    The quota process, in general terms, is a critical element of the 
Controlled Substances Act's regulatory system that seeks to prevent or 
limit diversion by preventing the accumulation of controlled substances 
in amounts exceeding legitimate need. The measures the proposed rule 
adopts to strengthen the system include authorizing the requisition 
from quota applicants of additional information helpful in detecting 
and preventing diversion, and ensuring that DEA's determinations 
regarding the appropriate quotas are adequately informed by input from 
other federal agencies, from the states, and from quota applicants.

[[Page 17330]]

Section-by-Section Analysis

Section 1303.11--Aggregate Production Quotas

    Section 1303.11 in the existing regulations directs the 
Administrator of DEA to determine the total quantity of each basic 
class of controlled substance listed in schedule I or II needed in the 
calendar year for the medical, scientific, research and industrial 
needs of the United States, for lawful export, and for the 
establishment and maintenance of reserve stocks. Section 1303.11(b)(1)-
(4) identifies a number of factors that are categorically to be 
considered in determining aggregate production quotas--relating to 
total net disposal, net disposal trends, inventories and inventory 
trends, and demand--followed by a final catchall factor, (5), regarding 
factors to be considered as the Administrator finds relevant. The 
proposed rule would make two additions to the list of factors that must 
regularly be considered in setting the aggregate production quotas 
because of their importance.
    First, it would add to the list the extent of any diversion of the 
controlled substance in the class. This is relevant to ensure that the 
allowed aggregate production quota is limited to that needed to provide 
adequate supplies for the United States' legitimate needs.
    Second, the proposed rule would amend the list of factors to be 
considered in establishing these quotas to include relevant information 
from the Department of Health and Human Services (HHS) and its 
components, including the Food and Drug Administration (FDA), the 
Centers for Disease Control and Prevention (CDC), and the Centers for 
Medicare and Medicaid Services (CMS), as well as relevant information 
obtained from the states. Pursuant to 42 U.S.C. 242(a), HHS studies the 
use and misuse of controlled substances and provides, through the FDA, 
an annual report to the Attorney General concerning the quantities of 
controlled substances necessary to support the medicinal needs of the 
United States. The CDC and the CMS may also have relevant information, 
including information about the prevalence and patterns of drug abuse 
and the diversion of controlled substances to illicit use. The 
amendment would ensure that information will be requested from the 
relevant HHS components and will be considered in setting the aggregate 
production quotas.
    Regarding the states, the proposed rule would provide that the 
Administrator will consider information from the states in setting the 
aggregate production quotas and make additional changes enhancing their 
role in Sec.  1303.11(c). The states are critically situated to provide 
information about the extent of legitimate and illegitimate use of 
controlled substances because of their responsibilities for drug 
enforcement within their jurisdictions, including through the 
Prescription Drug Monitoring Programs, their responsibilities for 
administration of their health care systems, and their responsibilities 
for dealing with the human and social costs of drug abuse and 
diversion. States may have relevant information indicating that 
individual procurement quota requests reflect quantities which will in 
fact be diverted to illicit use, which may in turn yield an exaggerated 
picture of the aggregate production quotas needed for legitimate 
purposes. The proposed rule accordingly includes amendments to Sec.  
1303.11(c) which provide for (i) transmitting notices of proposed 
aggregate production quotas, and final aggregate production quota 
orders, to the state attorney general, and (ii) holding a hearing if 
necessary to resolve an issue of material fact raised by a state's 
objection to a proposed aggregate production quota as excessive in 
relation to legitimate United States need.

Section 1303.12--Procurement Quotas

    Section 1303.12 in the regulations directs the Administrator to 
issue procurement quotas for manufacturers that use controlled 
substances to put them into dosage form or to make other substances. 
The section requires applicants for procurement quotas to state what 
basic class of controlled substance is needed, the purpose or purposes 
for which the class is desired, the quantity desired for each purpose 
during the next calendar year, and the quantities used and estimated to 
be used for each purpose during the current and preceding two calendar 
years. If the applicant's purpose is to manufacture another basic class 
of controlled substance, the applicant also must state the quantity of 
the other basic class that the applicant has applied to manufacture, 
and the quantity of the first basic class necessary to manufacture a 
specified quantity of the second basic class.
    The proposed rule would amend Sec.  1303.12(b) to clarify that the 
Administrator may require additional comparable information from 
applicants that may help to detect or prevent diversion, including 
customer identities and amounts of the controlled substance sold to 
each customer.

Section 1303.13--Adjustments of Aggregate Production Quotas

    Section 1303.13 authorizes the Administrator, at any time, to 
increase or reduce the aggregate production quotas for basic classes of 
controlled substances that were previously fixed pursuant to Sec.  
1303.11. The proposed rule would make amendments to Sec.  1303.13 that 
parallel some of the amendments made to Sec.  1303.11. Specifically, it 
includes changes in the extent of any diversion of the controlled 
substance among the factors to be considered in adjusting the aggregate 
production quota, requires transmission of adjustment notices and final 
adjustment orders to the state attorney general, and provides for a 
hearing if necessary to resolve an issue of material fact raised by a 
state's objection to a proposed adjusted quota as excessive for 
legitimate United States need.

Section 1303.22--Procedure for Applying for Individual Manufacturing 
Quotas

    The proposed rule would amend Sec.  1303.22 to clarify that the 
Administrator may require additional information from individual 
manufacturing quota applicants that may help to detect or prevent 
diversion, including customer identities and amounts of the controlled 
substance sold to each customer.

Section 1303.23--Procedures for Fixing Individual Manufacturing Quotas

    The proposed rule would amend Sec.  1303.23 to provide that the 
factors the Administrator may deem relevant in fixing individual 
manufacturing quotas include the extent and risk of diversion of 
controlled substances.

Section 1303.32--Purpose of Hearing

    The proposed rule includes an amendment relating to hearings in 
Sec.  1303.32(a), conforming to the amendments to Sec. Sec.  1303.11(c) 
and 1303.13(c) concerning hearings based on state objections.

Other Matters

    In addition to the significant changes discussed above, the 
proposed rule would correct a number of typographic errors in the 
current regulations.

Request for Comments

    Some of the proposed rule's provisions, including those relating to 
seeking information from other federal agencies and the states, and 
those relating to the holding of hearings based on state objections, 
are exempt from the notice and comment requirements of the 
Administrative Procedure Act as ``rules

[[Page 17331]]

of agency organization, procedure, or practice.'' 5 U.S.C. 553(b)(A). 
Regarding the other matters addressed in the proposed rule, DEA 
particularly seeks comments on the provisions regarding the factors the 
Administrator shall consider when adjusting the aggregate production 
quotas (21 CFR 1303.13(b)(1)) and the additional information the 
Administrator may require from applicants (21 CFR 1303.12(b) and 21 CFR 
1303.22).
    Insofar as soliciting public comment is necessary or useful, DEA 
publishes this proposed rule with a 15-day public comment period. This 
shortened period for public comment is necessary as an element in 
addressing the largest drug crisis in the nation's history. HHS and DEA 
have developed extensive information concerning the nature and 
magnitude of the crisis. See www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html; www.cdc.gov/drugoverdose/data (CDC Epidemic Data); 
www.cdc.gov/nchs/products/databriefs/db294.htm (CDC Overdose Data); 
www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.pdf (SAMHSA Data); www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis (NIDA Data); Drug Enforcement Administration, 2017 
National Drug Threat Assessment (Oct. 2017), at v, 25-43 (2017 DEA 
Data). Salient facts include the following:
    Drug overdoses are now the leading cause of injury-related death in 
the United States, eclipsing deaths from motor vehicle accidents, 
firearms, homicide, or suicide. There were more than 63,600 overdose 
deaths in 2016, with opioids as the main driver of such deaths. 
Overdoses involving opioids killed more than 42,000 people in 2016, 
with prescription opioids accounting for 40% of the total. Opioid 
overdose deaths were more than five times higher in 2016 than 1999. 
2017 DEA Data at v, 25; CDC Overdose Data; CDC Epidemic Data.
    The misuse of controlled prescription drugs, and particularly 
prescription opioids, has been central to this deadly epidemic. In 
2016, of Americans aged 12 or older, an estimated 3.3 million had 
misused prescription pain relievers during the preceding month and 
approximately 11.8 million had misused opioids in the past year. 
Prescription opioid misuse is more common than use of any category of 
illicit drug in the United States except for marijuana. SAMHSA Data at 
14, 16, 20-21.
    Users may be initiated into a life of substance abuse and 
dependency after first obtaining these drugs from their health care 
providers or without cost from the family medicine cabinet or from 
friends. Once ensnared, dependency on potent and dangerous street drugs 
may ensue. About 80% of heroin users first misused prescription 
opioids. Thus, it may be inferred that current users of heroin and 
fentanyl largely entered the gateway as part of the populations who 
previously misused prescription opioids. See NIDA Data.
    Street prices for controlled prescription opioids are typically 5 
to 10 times their retail value, with steady increases with the relative 
strength of the drug, fueling the market for prescription medications 
diverted into illegal channels. For example, hydrocodone combination 
products--a schedule II prescription drug and also the most prescribed 
controlled prescription drug in the country--can be purchased for $5 to 
$7 per tablet on the street. Slightly stronger drugs like oxycodone 
combined with acetaminophen (e.g., Percocet) can be purchased for $7 to 
$10 per tablet on the street. Even stronger prescription drugs are sold 
for as much as $1 per milligram (mg). For example, 30 mg oxycodone 
(immediate release) and 30 mg oxymorphone (extended release) cost $30 
to $40 per tablet on the street. Due in part to the large number of 
people who abuse licit controlled prescription drugs, other opioids are 
now being disguised and sold as controlled prescription drugs.
    The economic impact of prescription drug abuse was estimated to be 
$78.5 billion in 2013. Specific costs included increased health care 
and substance abuse treatment costs, criminal justice costs, and 
employment-related costs including lost earnings from premature death, 
reduced compensation, and lost employment. These costs, largely 
reflecting prescription opioid abuse, represent a substantial and 
growing economic burden on society. 2017 DEA Data at 40.
    This proposed rule's reforms, which will help to control the 
diversion of controlled substances feeding the crisis described above, 
must be implemented without delay to permit timely action by the Drug 
Enforcement Administration, informed by adequate input from 
manufacturers, other federal agencies, and the states. The affected 
determinations include the following:
    Section 1303.11 in the regulations requires the DEA Administrator 
to publish notice of the proposed aggregate production quotas for 2019 
well in advance in 2018. The proposed rule's amendments to Sec.  
1303.11 would expand the factors to be considered by the Administrator 
to include the extent of diversion and enhance the input and role of 
other federal agencies and the states in the quota-setting process. 
Having these reforms in place expeditiously will facilitate the sound 
proposal and determination of aggregate production quotas for 2019.
    Section 1303.12 requires the Administrator to set manufacturers' 
procurement quotas for 2019 well in advance in 2018; manufacturers' 
applications were due by April 1, 2018. The proposed rule would amend 
Sec.  1303.12 to allow the Administrator to require procurement quota 
applicants to provide additional information that may help to detect or 
prevent the diversion of controlled substances ostensibly obtained for 
legitimate dosage form manufacturing. Having this reform in place 
expeditiously will facilitate the sound determination of procurement 
quotas for 2019 and help to ensure that controlled substances sought 
for dosage form manufacturing will not be diverted.
    Section 1303.13 allows the Administrator to increase or reduce 
aggregate production quotas at any time. The proposed amendments would 
expand the factors to be considered by the Administrator in adjusting 
aggregate production quotas to include changes in the extent of 
diversion and make other changes to enhance the input and role of the 
states in the aggregate production quota adjustment process. Having 
these reforms in place expeditiously, as well as the amendments to 
other sections authorizing the requisition of more information from 
manufacturers bearing on the extent of diversion, will facilitate the 
sound determination of aggregate production quota adjustments by the 
Administrator, which may be undertaken at any time.
    Sections 1303.22 and 1303.23 require the Administrator to set 
individual manufacturing quotas for 2019 well in advance in 2018, based 
on applications the manufacturers must submit by May 1, 2018. The 
proposed rule's amendments to these sections would authorize the 
Administrator to require applicants to provide additional information 
that may help to detect or prevent diversion, and add the extent and 
risk of diversion to the factors the Administrator may deem relevant in 
fixing individual manufacturing quotas. Having these reforms in place 
expeditiously will facilitate the sound determination of the individual 
manufacturing quotas for 2019.
    In sum, the death of over 63,600 Americans from drug overdoses in 
2016, and the other human, social, and

[[Page 17332]]

economic costs detailed above, make imperative the immediate use of all 
available tools to prevent the diversion of controlled substances. 
Delay in the finalization and implementation of this proposed rule 
would impede putting into effect the diversion countermeasures it 
authorizes, which will help to stem a source of the flow of controlled 
substances with legitimate uses into illicit channels. Such delay would 
prevent in the meantime the alleviation of the toll on human life and 
health, and the devastating social and economic costs, which shortfalls 
in the existing regulations facilitate.

Regulatory Flexibility Act

    The Administrator, in accordance with the Regulatory Flexibility 
Act (5 U.S.C. 601-612), has reviewed this proposed rule and by 
approving it certifies that the rule will not have a significant 
economic impact on a substantial number of small entities.
    The DEA estimates that 325 manufacturers may be affected by the 
proposed rule, of which 301 manufacturers (92.6% of the total) are 
small entities. There will not be a significant economic impact on a 
substantial number of these small entities or any others because, as 
the ensuing certifications discuss, any overall cost of the rule is not 
significant.

Executive Orders 12866, 13563, and 13771--Regulatory Planning and 
Review, and Reducing Regulation and Controlling Regulatory Costs

    This regulation has been drafted and reviewed in accordance with 
Executive Order 12866, ``Regulatory Planning and Review,'' section 
1(b), Principles of Regulation, and Executive Order 13563, ``Improving 
Regulation and Regulatory Review.'' DEA has determined that this 
proposed rule is not a ``significant regulatory action'' under 
Executive Order 12866, section 3(f). The DEA analyzed the economic 
impact of each provision of this proposed rule. Section 1303.11 would 
be amended to make two additions to the list of factors to be 
considered by the Administrator in setting the aggregate production 
quotas. First, it would add the extent of any diversion of the 
controlled substance in the class. Second, it would add relevant 
information from HHS and its components, as well as from the states. 
The DEA has always considered any information obtained from other 
federal and state government agencies when fixing the aggregate 
production quotas for a controlled substance. While the DEA may receive 
additional information that is valuable in detecting and preventing 
diversion, the DEA has no reason to believe that there will be adverse 
economic impact or other consequences sufficient to implicate Executive 
Order (E.O.) 12866.
    Additionally, sections 1303.11 and 1303.13 would be amended to 
require the DEA to transmit copies of aggregate production quotas and 
any adjustments to those quotas published in the Federal Register 
directly to state attorney general. While the DEA anticipates some 
labor burden to transmit aggregate production quota notices and orders 
to each state attorney general, the DEA estimates that this activity 
will result in a minimal yearly cost to the DEA and that the DEA has 
sufficient resources to absorb this minimal cost.
    Additionally, sections 1303.11, 1303.13, and 1303.32 would be 
amended to explicitly state that the DEA Administrator shall hold a 
hearing if he or she determines it is necessary to resolve an issue of 
material fact raised by a state objecting to the proposed quantity for 
the class as excessive for legitimate United States need. The estimated 
yearly cost of this revision will be dependent on the amount of 
hearings the DEA Administrator determines to be necessary to resolve an 
issue of material fact raised by a state regarding the aggregate 
production quota. Hearings regarding aggregate production quotas are 
infrequent and the DEA estimates that hearings of this type will 
continue to be infrequent under this proposed rule. For these reasons, 
the DEA does not expect a material increase in the number of hearings 
or in the associated costs to DEA or the states.
    Sections 1303.12 and 1303.22 would be amended to explicitly state 
that the Administrator may require additional information from an 
individual manufacturing or procurement quota applicant, including 
customer identities and amounts of controlled substances sold to each 
of their customers. Currently, the DEA can and does request additional 
information of this nature from quota applicants if deemed necessary. 
While affording the Administrator express regulatory authority to 
require such information may result in the receipt of additional 
information that is valuable in detecting and preventing diversion, it 
is not expected that the difference will have adverse economic impact 
or other consequences sufficient to implicate E.O. 12866.
    Sections 1303.11, 1303.13, and 1303.23 would be amended to add the 
requirement that DEA consider diversion of a controlled substance when 
fixing aggregate production quotas, adjusting aggregate production 
quotas, and fixing individual manufacturing quotas. When fixing and 
adjusting the aggregate production quota, or fixing an individual 
manufacturing quota for a controlled substance, the DEA has always 
considered all available information regarding the diversion of that 
controlled substance. While the proposed rule's amendments, as 
discussed above, may result in the receipt and consideration of 
additional information relating to diversion, it is not expected that 
the difference will have adverse economic impact or other consequences 
sufficient to implicate E.O. 12866.
    This proposed rule is not expected to be an E.O. 13771 regulatory 
action because this proposed rule is not significant under E.O. 12866.

Executive Order 13132--Federalism

    This regulation will not have substantial direct effects on the 
states, on the relationship between the national Government and the 
states, or on the distribution of power and responsibilities among the 
various levels of government. Therefore, in accordance with Executive 
Order 13132, it is determined that this proposed rule does not have 
sufficient federalism implications to warrant the preparation of a 
federalism assessment.

Executive Order 12988--Civil Justice Reform

    This regulation meets the applicable standards set forth in 
sections 3(a) and 3(b)(2) of Executive Order 12988.

Paperwork Reduction Act

    This proposed rule codifies current agency practice under existing 
approved information collections, and does not impose new information 
collection requirements under the Paperwork Reduction Act of 1995, 44 
U.S.C. 3501-3521.

Unfunded Mandates Reform Act of 1995

    This proposed rule will not result in the expenditure by State, 
local and tribal governments, in the aggregate, or by the private 
sector, of $100 million or more in any one year, and it will not 
significantly or uniquely affect small governments. Therefore, no 
actions were deemed necessary under the provisions of the Unfunded 
Mandates Reform Act of 1995.

Congressional Review Act

    This rulemaking is not a major rule as defined by section 251 of 
the Congressional Review Act. 5 U.S.C. 804. This proposed rule will not 
result in an

[[Page 17333]]

annual effect on the economy of $100 million or more; a major increase 
in costs or prices; or significant adverse effects on competition, 
employment, investment, productivity, or innovation, or on the ability 
of United States-based enterprises to compete with foreign-based 
enterprises in domestic and export markets.

List of Subjects in 21 CFR Part 1303

    Administrative practice and procedure, Drug traffic control.

    Accordingly, for the reasons stated in the preamble, part 1303 of 
title 21 of the Code of Federal Regulations is proposed to be amended 
as follows:

PART 1303--QUOTAS

0
1. The authority citation for part 1303 continues to read as follows:

    Authority:  21 U.S.C. 821, 826, 871(b).

0
2. In Sec.  1303.11:
0
a. Remove the word ``and'' at the end of paragraph (b)(4).
0
b. Redesignate paragraph (b)(5) as paragraph (b)(7).
0
c. Add new paragraphs (b)(5) and (6).
0
d. In paragraph (c), add the phrase ``and transmitted to each state 
attorney general'' before the period in the second sentence, add the 
phrase ``except that the Administrator shall hold a hearing if he 
determines it is necessary to resolve an issue of material fact raised 
by a state objecting to the proposed quantity for the class as 
excessive for legitimate United States need'' before the period in the 
fourth sentence, remove the word ``such'' in the fifth sentence, add 
the phrase ``, the Administrator'' before ``shall issue'' in the sixth 
sentence, and add the phrase ``and transmitted to each state attorney 
general'' before the period in the final sentence.
    The additions read as follows:


Sec.  1303.11   Aggregate production quotas.

* * * * *
    (b) * * *
    (5) The extent of any diversion of the controlled substance in the 
class;
    (6) Relevant information obtained from the Department of Health and 
Human Services, including from the Food and Drug Administration, the 
Centers for Disease Control and Prevention, and the Centers for 
Medicare and Medicaid Services, and relevant information obtained from 
the states; and
* * * * *
0
3. In Sec.  1303.12(b), add after the fifth sentence a new sentence to 
read as follows:


Sec.  1303.12   Procurement quotas.

* * * * *
    (b) * * * The Administrator may require additional information from 
an applicant which, in the Administrator's judgment, may be helpful in 
detecting or preventing diversion, including customer identities and 
amounts of the controlled substance sold to each customer. * * *
* * * * *
0
4. In Sec.  1303.13:
0
a. Revise paragraph (b)(1).
0
b. In paragraph (c), add the phrase ``and transmitted to each state 
attorney general'' before the period in the second sentence, add the 
phrase ``, except that the Administrator shall hold a hearing if he 
determines it is necessary to resolve an issue of material fact raised 
by a state objecting to the proposed adjusted quota as excessive for 
legitimate United States need'' before the period in the fourth 
sentence, remove the word ``such'' in the fifth sentence, and add the 
phrase ``and transmitted to each state attorney general'' before the 
period in the final sentence.
    The revision reads as follows:


Sec.  1303.13   Adjustments of aggregate production quotas.

* * * * *
    (b) * * *
    (1) Changes in the demand for that class, changes in the national 
rate of net disposal of the class, changes in the rate of net disposal 
of the class by registrants holding individual manufacturing quotas for 
that class, and changes in the extent of any diversion in the class;
* * * * *


Sec.  1303.21   [Amended]

0
5. In Sec.  1303.21(a), remove ``Sec. Sec.  '' in the second sentence 
and add in its place ``Sec.  ''.
0
6. In Sec.  1303.22:
0
a. In paragraph (c)(2), remove the word ``econolic'' and add in its 
place the word ``economic''.
0
b. Add paragraph (d).
    The addition reads as follows:


Sec.  1303.22   Procedure for applying for individual manufacturing 
quotas.

* * * * *
    (d) The Administrator may require additional information from an 
applicant which, in the Administrator's judgment, may be helpful in 
detecting or preventing diversion, including customer identities and 
amounts of the controlled substance sold to each customer.


Sec.  1303.23   [Amended]

0
7. In Sec.  1303.23, add the phrase ``the extent of any diversion of 
the controlled substance,'' after ``strikes),'' in paragraph (a)(2), 
and add the phrase ``any risk of diversion of the controlled 
substance,'' after ``strikes),'' in paragraph (b)(2).


Sec.  1303.32   [Amended]

0
8. In Sec.  1303.32(a), add the phrase ``and shall, if determined by 
the Administrator to be necessary under Sec.  1303.11(c) or 1303.13(c) 
based on objection by a state,'' before ``hold a hearing''.

    Dated: April 13, 2018.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2018-08111 Filed 4-18-18; 8:45 am]
 BILLING CODE 4410-09-P